Quick Search:       Advanced Search
Chinese Version 
Online office
Journal Online
Download
Top
Links

扫描微信二维码,获取更多信息
A randomized controlled trial comparing total glucosides of paeony capsule and compound glycyrrhizin tablet for alopecia areata
  
View Full Text  View/Add Comment  Download reader
KeyWord:total glucosides of paeony capsule  compound glycyrrhizin tablets  T-cell subsets  alopecia areata
Author NameAffiliationE-mail
Ding-quan Yang Department of Dermatology, China-Japan Friendship Hospital, Beijing, 100029, China  
Li-ping You Department of Dermatology, China-Japan Friendship Hospital, Beijing, 100029, China  
Pei-hua Song Department of Dermatology, China-Japan Friendship Hospital, Beijing, 100029, China  
Li-xin Zhang Department of Dermatology, China-Japan Friendship Hospital, Beijing, 100029, China  
Yan-ping Bai Department of Dermatology, China-Japan Friendship Hospital, Beijing, 100029, China zhi@tsinghua.edu.cn 
Hits: 1154
Download times: 63
Abstract:
      

Objective

To observe the efficacy and safety of total glucosides of paeony capsule (TGPC) in patients with mild and moderate alopecia areata.

Methods

A total of 86 outpatients were randomly allocated into two groups of TGPC (treatment, 44 cases) and compound glycyrrhizin tablet (control, 42 cases). The treatment group was given oral TGPC, three times daily and 600 mg per time; the control group was given oral compound glycyrrhizin tablets, three times daily and 50 mg per time. In addition, both groups were given 10 mg of vitamin B2 and tapped the bold patches with massage. The treatment course was three months for both groups. Peripheral blood T-cell subsets (CD3+CD4+, CD3+CD8+, Th, Ts, Th/Ts) of 10 patients randomly selected from each group respectively were tested before and after three months of treatment. The effectiveness and adverse reaction of all cases were observed each month. The safety was evaluated according to the incidence rate of adverse reaction.

Results

In the treatment group, the cured and markedly effective rate was 36.36% (16/44), 50.00% (22/44) and 68.18% (30/44) at the end of first, second and third month of treatment, respectively, and the incidence rate of adverse reaction was 13.64% (6/44). In the control group, the cured and markedly effective rate was 38.10% (16/42), 57.14% (24/42) and 71.43% (30/42), respectively, and the incidence rate of adverse reaction was 16.67% (7/42). The cured and markedly effective rate and the incidence rate of adverse reaction were similar in both groups (P>0.05). TGPC and compound glycyrrhizin tablet can inhibit CD3+CD4+ and CD3+CD8+, and decrease the ratio of Th/Ts (P<0.05).

Conclusion

TGPC is effective and safe in the treatment of alopecia areata.
Close